Condition
End Stage Kidney Disease (ESKD)
Total Trials
4
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Not Applicable (3)
P 1 (1)
Trial Status
Not Yet Recruiting3
Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07738731Not ApplicableNot Yet Recruiting
Dialysis Less Frequently in the Elderly
NCT07619820Phase 1RecruitingPrimary
A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)
NCT07685223Not ApplicableNot Yet RecruitingPrimary
Medium Cut-Off and High-Flux Membranes on Mineral and Bone Metabolism in Hemodialysis Patients
NCT07679763Not ApplicableNot Yet RecruitingPrimary
Randomized Cross-Over Comparison of Medium Cut-Off and High-Flux Hemodialysis Membranes
Showing all 4 trials